Longitudinal imaging of Alzheimer pathology using [ 11C]PIB, [ 18F]FDDNP and [ 18F]FDG PET

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 6, 2012, Pages 990-1000

  Ossenkoppele, Rik ^a,b   Tolboom, Nelleke ^a,b   Foster Dingley, Jessica C ^b   Adriaanse, Sofie F ^a,b   Boellaard, Ronald ^b   Yaqub, Maqsood ^b   Windhorst, Albert D ^b   Barkhof, Frederik ^b   Lammertsma, Adriaan A ^b   Scheltens, Philip ^a   Van Der Flier, Wiesje M ^a,b   Van Berckel, Bart N M ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

18F FDDNP; 11C PIB; 18F FDG; Alzheimer's disease; Positron emission tomography

Indexed keywords

[2 [1 [6 [(2 [18F]FLUOROETHYL)(METHYL)AMINO] 2 NAPHTHYL]ETHYLIDENE]MALONONONITRILE]; CARBON 11; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B; TRACER; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; FRONTAL LOBE; HUMAN; LONGITUDINAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; TEMPORAL LOBE;

AGED; ALZHEIMER DISEASE; ANILINE COMPOUNDS; BENZOTHIAZOLES; CASE-CONTROL STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NITRILES; POSITRON-EMISSION TOMOGRAPHY; STILBENES; TIME FACTORS;

EID: 84862646168     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2102-3     Document Type: Article

References (41)

1. JL Cummings 2004 Alzheimer's disease N Engl J Med 351 56 67 15229308 10.1056/NEJMra040223 1:CAS:528:DC%2BD2cXltlOjsb8%3D
2. CJ Stam W de Haan A Daffertshofer BF Jones I Manshanden AM van Cappellen van Walsum, et al. 2009 Graph theoretical analysis of magnetoencephalographic functional connectivity in Alzheimer's disease Brain 132 213 224 18952674 10.1093/brain/awn262 1:STN:280:DC%2BD1M%2Fpt1Oitg%3D%3D
3. DHS Silverman GW Small CY Chang CS Lu MAK de Aburto W Chen, et al. 2001 Positron emission tomography in evaluation of dementia JAMA 286 2120 2127 11694153 10.1001/jama.286.17.2120 1:STN:280:DC%2BD3MnmvFCrsA%3D%3D
4. WE Klunk H Engler A Nordberg Y Wang G Blomquist DP Holt, et al. 2004 Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B Ann Neurol 55 306 319 14991808 10.1002/ana.20009 1:CAS:528:DC%2BD2cXisFKntb8%3D
5. GW Small V Kepe LM Ercoli P Siddarth SY Bookheimer KJ Miller, et al. 2006 PET of brain amyloid and Tau in mild cognitive impairment N Engl J Med 355 2652 2663 17182990 10.1056/NEJMoa054625 1:CAS:528:DC%2BD28XhtlGhtLvL
6. N Tolboom M Yaqub WM van der Flier R Boellaard G Luurtsema AD Windhorst, et al. 2009 Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET J Nucl Med 50 191 197 19164243 10.2967/jnumed.108.056499
7. N Tolboom WM Flier J Boverhoff M Yaqub M Wattjes PG Raijmakers, et al. 2010 Molecular imaging in the diagnosis of Alzheimer's disease: visual interpretation of [11C]PIB and [18F]FDDNP PET images J Neurol Neurosurg Psychiatry 81 882 884 20543188 10.1136/jnnp.2009.194779
8. S Ng VL Villemagne S Berlangieri ST Lee M Cherk SJ Gong, et al. 2007 Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease J Nucl Med 48 547 552 17401090 10.2967/jnumed.106.037762 1:CAS:528:DC%2BD2sXhtVert7nO
9. A Forsberg H Engler O Almkvist G Blomquist G Hagman A Wall, et al. 2008 PET imaging of amyloid deposition in patients with mild cognitive impairment Neurobiol Aging 29 1456 1465 17499392 10.1016/j.neurobiolaging.2007.03.029 1:CAS:528:DC%2BD1cXhtVSjsr%2FI
10. A Okello J Koivunen P Edison HA Archer FE Turkheimer K Nagren, et al. 2009 Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study Neurology 73 754 760 19587325 10.1212/WNL.0b013e3181b23564 1:CAS:528:DC%2BD1MXhtVKrsbvF
11. VL Villemagne K Pike G Chetelat KA Ellis R Mulligan P Bourgeat, et al. 2011 Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease Ann Neurol 69 181 192 21280088 10.1002/ana.22248 1:CAS:528: DC%2BC3MXisVCisLs%3D
12. J Koivunen M Scheinin JR Virta S Aalto T Vahlberg K Nagren, et al. 2011 Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study Neurology 76 1085 1090 21325653 10.1212/WNL.0b013e318212015e 1:STN:280:DC%2BC3M3ot1Klsg%3D%3D
13. H Engler A Forsberg O Almkvist G Blomquist E Larsson I Savitcheva, et al. 2006 Two-year follow-up of amyloid deposition in patients with Alzheimer's disease Brain 129 2856 2866 16854944 10.1093/brain/awl178
14. A Kadir O Almkvist A Forsberg A Wall H Engler B Långström, et al. 2012 Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease Neurobiol Aging 33 198.e1 198.e14 10.1016/j.neurobiolaging. 2010.06.015
15. NM Scheinin S Aalto J Koikkalainen J Lotjonen M Karrasch N Kemppainen, et al. 2009 Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls Neurology 73 1186 1192 19726751 10.1212/WNL.0b013e3181bacf1b 1:CAS:528:DC%2BD1MXht1antrfM
16. CR Jack Jr VJ Lowe SD Weigand HJ Wiste ML Senjem DS Knopman, et al. 2009 The Alzheimer's disease neuroimaging initiative. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease Brain 132 1355 1365 19339253 10.1093/brain/awp062
17. JO Rinne DJ Brooks MN Rossor NC Fox R Bullock WE Klunk, et al. 2010 11C-PiB PET assessment of change in fibrillar amyloid-[beta] load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study Lancet Neurol 9 363 372 20189881 10.1016/S1474-4422(10)70043-0 1:CAS:528:DC%2BC3cXltF2kt7Y%3D
18. J Shin SY Lee SH Kim YB Kim SJ Cho 2008 Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease Neuroimage 43 236 244 18694837 10.1016/j.neuroimage.2008.07.022
19. ED Agdeppa V Kepe J Liu S Flores-Torres N Satyamurthy A Petric, et al. 2001 Binding characteristics of radiofluorinated 6-dialkylamino-2- naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease J Neurosci 21 RC189 11734604 1:STN:280:DC%2BD3MnptlejtA%3D%3D
20. G McKhann D Drachman M Folstein R Katzman D Price EM Stadlan 1984 Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease Neurology 34 939 944 6610841 1:STN:280:DyaL2c3ks1altQ%3D%3D
21. RC Petersen GE Smith SC Waring RJ Ivnik EG Tangalos E Kokmen 1999 Mild cognitive impairment: clinical characterization and outcome Arch Neurol 56 303 908 10190820 10.1001/archneur.56.3.303 1:STN:280:DyaK1M3gsFSqtw%3D%3D
22. G Brix J Zaers LE Adam ME Bellemann H Ostertag H Trojan, et al. 1997 Performance evaluation of a whole-body PET scanner using the NEMA protocol J Nucl Med 38 1614 1623 9379202 1:STN:280:DyaK1c%2FitFOmtw%3D%3D
23. AA Wilson A Garcia A Chestaskova HF Kung SA Houle 2004 A rapid one-step radiosynthesis of the beta-amyloid imaging radiotracer N-methyl-[C-11]2-('4- methylaminophenyl)-6-hydroxybenzothiazole ([C-11]-6-OH-BTA-1) J Labelled Comp Radiopharm 47 679 682 10.1002/jlcr.854 1:CAS:528:DC%2BD2cXovVOqsLg%3D
24. RP Klok PJ Klein BNM van Berckel N Tolboom AA Lammertsma AD Windhorst 2008 Synthesis of 2-(1,1-dicyanopropen-2-yl)-6-(2-[18F]-fluoroethyl)- methylamino-naphthalene ([18F]FDDNP) Appl Radiat Isot 66 203 207 18053733 10.1016/j.apradiso.2007.10.008 1:CAS:528:DC%2BD2sXhsVKkurnL
25. C Svarer K Madsen SG Hasselbalch LH Pinborg S Haugbol VG Frokjaer, et al. 2005 MR-based automatic delineation of volumes of interest in human brain PET images using probability maps Neuroimage 24 969 979 15670674 10.1016/j.neuroimage.2004.10.017
26. Y Wu R Carson 2002 Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging J Cereb Blood Flow Metab 22 1440 1452 12468889 10.1097/00004647-200212000-00004
27. M Yaqub N Tolboom R Boellaard BNM van Berckel EW van Tilburg G Luurtsema, et al. 2008 Simplified parametric methods for [11C]PIB studies Neuroimage 42 76 86 18541442 10.1016/j.neuroimage.2008.04.251
28. M Yaqub N Tolboom BNM van Berckel P Scheltens AA Lammertsma R Boellaard 2010 Simplified parametric methods for [18F]FDDNP studies Neuroimage 49 433 441 19643186 10.1016/j.neuroimage.2009.07.046
29. H Yamaguchi S Hirai M Morimatsu M Shoji Y Nakazato 1989 Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by beta protein immunostain Acta Neuropathol 77 314 319 2466390 10.1007/BF00687584 1:STN:280:DyaL1M7mtlOjug%3D%3D
30. CR Jack Jr DS Knopman WJ Jagust LM Shaw PS Aisen MW Weiner, et al. 2010 Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 119 128 20083042 10.1016/S1474-4422(09)70299-6 1:CAS:528:DC%2BC3cXhtFeru74%3D
31. JA Hardy DJ Selkoe 2002 The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 197 353 356 10.1126/science.1072994
32. BT Hyman K Marzloff PV Arriagada 1993 The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution J Neuropathol Exp Neurol 52 594 600 8229078 10.1097/00005072-199311000-00006 1:STN:280:DyaK2c%2FksFOltA%3D%3D
33. RH Christie BJ Bacskai WR Zipfel RM Williams ST Kajdasz WW Webb, et al. 2001 Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy J Neurosci 21 858 864 11157072 1:CAS:528:DC%2BD3MXht1Sjsr8%3D
34. FH Bouwman WM van der Flier NSM Schoonenboom EJ van Elk A Kok F Rijmen, et al. 2007 Longitudinal changes of CSF biomarkers in memory clinic patients Neurology 69 1006 1011 17785669 10.1212/01.wnl.0000271375.37131.04 1:CAS:528:DC%2BD2sXpsFajurw%3D
35. PW Thompson L Ye JL Morgenstern L Sue TG Beach DJ Judd, et al. 2009 Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies J Neurochem 109 623 630 19226369 10.1111/j.1471-4159.2009. 05996.x 1:CAS:528:DC%2BD1MXksVKnsro%3D
36. N Tolboom WM van der Flier M Yaqub R Boellaard NA Verwey MA Blankenstein, et al. 2009 Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding J Nucl Med 50 1464 1470 19690025 10.2967/jnumed.109.064360 1:CAS:528:DC%2BD1MXhtFOrtbvN
37. N Tolboom WM Flier M Yaqub T Koene R Boellaard AD Windhorst, et al. 2009 Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment Neurology 73 2079 2085 20018636 10.1212/WNL.0b013e3181c679cc 1:STN:280:DC%2BD1MfjtFOitg%3D%3D
38. GE Alexander K Chen P Pietrini SI Rapoport EM Reiman 2002 Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies Am J Psychiatry 159 738 745 11986126 10.1176/appi.ajp.159.5.738
39. Forster S, Grimmer T, Miederer I, Henriksen G, Yousefi BH, Graner P, et al. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. Biol Psychiatry 2011. doi: 10.1016/j.biopsych. 2011.04.023
40. AE van der Vlies ELGE Koedam YAL Pijnenburg JWR Twisk P Scheltens WM van der Flier 2009 Most rapid cognitive decline in APOE E4 negative Alzheimer's disease with early onset Psychol Med 39 1907 1911 19335933 10.1017/ S0033291709005492
41. Verhage F. Intelligentie en leeftijd: onderzoek bij Nederlanders van twaalf tot zevenenzeventig jaar [Intelligence and age: study with Dutch people aged 12 to 77]. Assen: Van Gorcum; 1964.